GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

EuBiologics Co 206650.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

8,090

+2.02%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About EuBiologics Co

Its shares trade on KOSDAQ under the ticker 206650.KQ. It has been listed since 24 January 2017. In the fiscal year to 30 September 2025, it reported revenue of ₩149.20bn and net income of ₩41.26bn. At that date it held total assets of ₩240.23bn and shareholders' equity of ₩175.36bn.

EuBiologics Co., Ltd. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2017-01-24. The firm operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
24 Jan 2017
Employees
323

Leadership

Pay as last reported

  • Yeong Ok BaekChief Executive Officer, Director, since 2023
  • Gyeong Ho MinAssistant Managing Director
  • Byeong Ho ChoiInternal Auditor
  • Yeong Sin ParkAssistant Managing Director
  • Ho Gyeong KangDirector
  • Deok Sang KimDirector
  • Yeong Mok GilNon-Executive Independent Director
  • Mr. Glenn RockmanNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • EuBiologics develops oral cholera vaccines in the Vaccine segment.
  • The CRMO segment provides biopharmaceutical contract research and manufacturing services.
  • EuBiologics has 323 employees focused on biopharmaceutical innovation.

Weaknesses

  • The company's Vaccine segment relies on oral cholera vaccines only.
  • The CRMO segment faces competition from global biopharmaceutical firms.
  • EuBiologics has no presence in emerging markets like India or Brazil.

Opportunities

  • Expanding the Vaccine segment into new countries such as Vietnam and Thailand.
  • Growing demand for biopharmaceutical services in the CRMO segment.
  • Increasing global health initiatives targeting cholera prevention.

Threats

  • Rising costs of raw materials for vaccine production in Korea.
  • Regulatory changes affecting biopharmaceutical manufacturing in Seoul.
  • Competition from established biotech firms in the Health Care sector.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.